TCL Archive In Brief: Panel Meeting Canceled; New Senior Executive Service Draws Enthusiastic Response At NCI July 13, 1979
TCL Archive NCI Needs $107 Million More In FY 1982 Than Asked for Key Programs, R01s And P01s, New Initiatives April 17, 1981
TCL Archive FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says. January 14, 2005